肾衰方对慢性肾衰竭大鼠微炎症状态影响
|
摘要
目的:观察不同组别药物在控制慢性肾衰竭(CRF)模型大鼠微炎症状态的疗效差别反向探析不同中医病理机制在CRF发病过程中占据的地位及对疾病的发展。方法:将70只SD大鼠随机分成空白对照组,模型组,补益组,化瘀组,泄浊组,肾衰方组及氯沙坦组,除空白对照组外均按照Yokozawa法复制慢性肾衰模型。造模后各组开始灌胃。8周后取血检测大鼠的血肌酐(Scr)、血尿素氮(BUN)、血尿酸(UA)、血浆C反应蛋白(CRP)、白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)数据并进行统计学分析。结果:与模型组比较,泄浊组、肾衰方组Scr水平降低(P<0.05);肾衰方组BUN水平降低;补益组、泄浊组、肾衰方组、氯沙坦组UA水平降低(P<0.05)。与模型组比较,泄浊组、肾衰方组TNF-α、IL-6、CRP水平均水平降低(P<0.05);氯沙坦组IL-6水平降低。与补益组比较,泄浊组TNF-α、IL-6、CRP水平均降低(P<0.05);肾衰方组TNF-α、CRP水平均降低(P<0.05)。与化瘀组比较,泄浊组、肾衰方组TNF-α、IL-6、CRP水平均降低(P<0.05)。结论:肾衰方能有效保护CRF大鼠肾功能;肾衰方及泄浊组能改善CRF大鼠的微炎症状态,并反向表明湿浊证很可能是CRF微炎症状态的关键病理因素。
Objective:To observe the difference of curative between different groups of drugs in controlling the micro-inflammatory state of model rats with chronic renal failure and reversely explore the status of different TCM pathological development of it. Methods:Seventy SD rats were randomly divided into normal control group,model group,tonifying group,blood-circulating group,turbidity-dispelling group,Shenshuai Decoction group and losartan group. Except the rats of normal control group,all the CRF rats were established by the method of Yokozawa. After modeling,each group began to gavage. Eight weeks later,the blood of rats was collected and the data of Scr,BUN,UA,CRP,IL-6,TNF-α,in rat blood were measured and statistically analyzed. Results:Compared with model group,the level of Scr was lower than turbiditydispelling group and Shenshuai Decoction group(P<0.05);the level of BUN was lower than tonifying group,turbidity-dispelling group and Shenshuai Decoction group(P<0.05). Compared with model group,the level of TNF-α,IL-6 and CRP were lower than turbidity-dispelling group and Shenshuai Decoction group(P<0.05);IL-6 levels in the Losartan group were lower. Compared with tonifying group,the level of TNF-α,IL-6 and CRP in the turbidity-dispelling group lower(P<0.05);the levels of TNF-αand CRP were lower in the Shenshuai Decoction group(P<0.05). Compared with blood-circulating group,the levels of TNF-α,IL-6 and CRP were lower than turbidity-dispelling group and Shenshuai Decoction group(P<0.05). Conclusion:Shenshuai Decoction can effectively protect renal function in CRF rats. Shenshuai Decoction and turbidity-dispelling group can relieve the micro-inflammatory state of CRF rats,and reversely shows that turbidity may be the key pathological factor of micro-inflammatory state.
Objective:To observe the difference of curative between different groups of drugs in controlling the micro-inflammatory state of model rats with chronic renal failure and reversely explore the status of different TCM pathological development of it. Methods:Seventy SD rats were randomly divided into normal control group,model group,tonifying group,blood-circulating group,turbidity-dispelling group,Shenshuai Decoction group and losartan group. Except the rats of normal control group,all the CRF rats were established by the method of Yokozawa. After modeling,each group began to gavage. Eight weeks later,the blood of rats was collected and the data of Scr,BUN,UA,CRP,IL-6,TNF-α,in rat blood were measured and statistically analyzed. Results:Compared with model group,the level of Scr was lower than turbiditydispelling group and Shenshuai Decoction group(P<0.05);the level of BUN was lower than tonifying group,turbidity-dispelling group and Shenshuai Decoction group(P<0.05). Compared with model group,the level of TNF-α,IL-6 and CRP were lower than turbidity-dispelling group and Shenshuai Decoction group(P<0.05);IL-6 levels in the Losartan group were lower. Compared with tonifying group,the level of TNF-α,IL-6 and CRP in the turbidity-dispelling group lower(P<0.05);the levels of TNF-αand CRP were lower in the Shenshuai Decoction group(P<0.05). Compared with blood-circulating group,the levels of TNF-α,IL-6 and CRP were lower than turbidity-dispelling group and Shenshuai Decoction group(P<0.05). Conclusion:Shenshuai Decoction can effectively protect renal function in CRF rats. Shenshuai Decoction and turbidity-dispelling group can relieve the micro-inflammatory state of CRF rats,and reversely shows that turbidity may be the key pathological factor of micro-inflammatory state.
引文
[1]葛均波,徐永建.内科学[M].北京:人民卫生出版社,2013,524.
[2]GA Kaysen. The Microinflammatory State in Uremia:Causes and Potential Consequences[J].J Am Soc Nephrol,2001,12(7):1549-1557.
[3]M Schomig,A Eisenhardt. The Microinflammatory State of Uremia[J]. Blood Purif,2000,18(4):327-332.
[4]Y Lu,YT Jeong. Emodin isolated polygoni cuspidati radix inhibits TNF-αand IL-6 release by blockading NF-κB and MAP Kinase Pathways in Mast Cells Stimulated with PMA Plus A23187[J].Biomol Ther,2013,21(6):435-441.
[5]王谦,耿益民.几种中药有效成分对大鼠系膜细胞IL-6 mRNA表达的影响[J].中国病理生理杂志,2001,17(1):23-24.
[6]Li M,Zhang L. Lipid-soluble extracts from Salvia miltiorrhiza inhibit production of LPS-induced inflammatory mediators via NF-κB modulation in RAW 264.7 cells and perform antiinflammatory effects in vivo[J]. Phytother Res,2012,26(8):1195-1204.
[7]金涛,王晓梅.黄芪注射液对糖尿病性心肌病患者血清黏附及C反应蛋白的影响[J].徐州医学院学报,2009,29(1):40-42.
[8]T Yokozawa,PD Zheng. Animal model of adenine-induced chronic renal failure in rats[J]. Nephron,1986,44(3):230-234.
[9]李成,房向东.大黄减轻慢性肾衰竭微炎症反应的研究进展[J].实用医学杂志,2012,28(18):2994-2996.
[10]张再康,王立新.慢性肾功能衰竭中医病机探讨[J].广州中医药大学学报,2008,25(5):389-391.
[11]刘旭生,黄丽娟.慢性肾衰竭中医证后分布规律探讨[J].中国中西医结合肾病杂志,2007,8(4):219-220.
[12]尹振祥,林美平.慢性肾衰竭的中医病因病机及其治疗探讨[J].中国中医急症,2006,15(2):166-167.
[13]朱辟疆,周逊.慢性肾功能衰竭微炎症状态与中医证型关系研究[J].现代中西医结合杂志,2008,17(5):652-654.
[2]GA Kaysen. The Microinflammatory State in Uremia:Causes and Potential Consequences[J].J Am Soc Nephrol,2001,12(7):1549-1557.
[3]M Schomig,A Eisenhardt. The Microinflammatory State of Uremia[J]. Blood Purif,2000,18(4):327-332.
[4]Y Lu,YT Jeong. Emodin isolated polygoni cuspidati radix inhibits TNF-αand IL-6 release by blockading NF-κB and MAP Kinase Pathways in Mast Cells Stimulated with PMA Plus A23187[J].Biomol Ther,2013,21(6):435-441.
[5]王谦,耿益民.几种中药有效成分对大鼠系膜细胞IL-6 mRNA表达的影响[J].中国病理生理杂志,2001,17(1):23-24.
[6]Li M,Zhang L. Lipid-soluble extracts from Salvia miltiorrhiza inhibit production of LPS-induced inflammatory mediators via NF-κB modulation in RAW 264.7 cells and perform antiinflammatory effects in vivo[J]. Phytother Res,2012,26(8):1195-1204.
[7]金涛,王晓梅.黄芪注射液对糖尿病性心肌病患者血清黏附及C反应蛋白的影响[J].徐州医学院学报,2009,29(1):40-42.
[8]T Yokozawa,PD Zheng. Animal model of adenine-induced chronic renal failure in rats[J]. Nephron,1986,44(3):230-234.
[9]李成,房向东.大黄减轻慢性肾衰竭微炎症反应的研究进展[J].实用医学杂志,2012,28(18):2994-2996.
[10]张再康,王立新.慢性肾功能衰竭中医病机探讨[J].广州中医药大学学报,2008,25(5):389-391.
[11]刘旭生,黄丽娟.慢性肾衰竭中医证后分布规律探讨[J].中国中西医结合肾病杂志,2007,8(4):219-220.
[12]尹振祥,林美平.慢性肾衰竭的中医病因病机及其治疗探讨[J].中国中医急症,2006,15(2):166-167.
[13]朱辟疆,周逊.慢性肾功能衰竭微炎症状态与中医证型关系研究[J].现代中西医结合杂志,2008,17(5):652-654.